Uptake of the lateral flow urine LAM test in Europe and Central Asia
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Uptake of the lateral flow urine LAM test in Europe and Central Asia. / Kraef, C.; Yedilbayev, A.; Seguy, N.; Bentzon, A.; Podlekareva, D.; Cirillo, D. M.; van der Werf, M. J.; Kirk, O.
I: International Journal of Tuberculosis and Lung Disease, Bind 26, Nr. 9, 2022, s. 835-841.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Uptake of the lateral flow urine LAM test in Europe and Central Asia
AU - Kraef, C.
AU - Yedilbayev, A.
AU - Seguy, N.
AU - Bentzon, A.
AU - Podlekareva, D.
AU - Cirillo, D. M.
AU - van der Werf, M. J.
AU - Kirk, O.
N1 - Publisher Copyright: © 2022 The Union.
PY - 2022
Y1 - 2022
N2 - INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of the test, we conducted an electronic survey among national focal points and managers of TB and HIV programmes in the 53 Member States of the WHO European Region and a European network of clinicians working in TB and HIV medicine. RESULTS: In all, 45 individual responses (37 countries) were received from programme managers and focal points and 17 responses (14 countries) from clinicians. Only eight countries reported adopting LF-LAM policies, with only four currently using the AlereLAM (Armenia, Belarus, Ukraine and Uzbekistan). The most commonly reported barriers to implementing the test were the small number of eligible patients (with HIV-TB co-infections), the test not being included in the TB or HIV programme's mandate and lack of budget allocation. CONCLUSION: Consistent with findings from high TB burden countries in Africa and Asia, the survey demonstrated that uptake of AlereLAM is almost nonexistent. Addressing the identified barriers and the intrinsic limitations of the test could help to increase the use of the test.
AB - INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of the test, we conducted an electronic survey among national focal points and managers of TB and HIV programmes in the 53 Member States of the WHO European Region and a European network of clinicians working in TB and HIV medicine. RESULTS: In all, 45 individual responses (37 countries) were received from programme managers and focal points and 17 responses (14 countries) from clinicians. Only eight countries reported adopting LF-LAM policies, with only four currently using the AlereLAM (Armenia, Belarus, Ukraine and Uzbekistan). The most commonly reported barriers to implementing the test were the small number of eligible patients (with HIV-TB co-infections), the test not being included in the TB or HIV programme's mandate and lack of budget allocation. CONCLUSION: Consistent with findings from high TB burden countries in Africa and Asia, the survey demonstrated that uptake of AlereLAM is almost nonexistent. Addressing the identified barriers and the intrinsic limitations of the test could help to increase the use of the test.
KW - HIV
KW - infection
KW - lung disease
KW - tuberculosis
U2 - 10.5588/ijtld.21.0656
DO - 10.5588/ijtld.21.0656
M3 - Journal article
C2 - 35996279
AN - SCOPUS:85136197791
VL - 26
SP - 835
EP - 841
JO - International Journal of Tuberculosis and Lung Disease
JF - International Journal of Tuberculosis and Lung Disease
SN - 1027-3719
IS - 9
ER -
ID: 321835451